Edwards Lifesciences (EW)

Company ID: 185 | CIK: 0001099800
10-Q view:
No 10-Q YTD data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

Business Unit / Product Segments

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Major Customers (% of Revenue)

Operational KPIs

Stockholders (customers)

No 10-Q data

Perfusionists (headcount)

Accounts receivable sold under securitization (other)

No 10-K data

Adjusted net sales growth (other)

No 10-K data

Anti-dilutive shares excluded (other)

No 10-K data

Cash and short-term investments (other)

No 10-K data

Cash held outside United States (other)

No 10-K data

Columbia Strategic Cash fund NAV (other)

No 10-K data

Common Shares Outstanding (other)

No 10-Q data

Common shares outstanding (other)

Consignment inventory (other)

No 10-K data

Countries selling transcatheter valves (other)

No 10-Q data

Countries served (other)

Countries where products sold (other)

No 10-Q data

Countries with THV availability (other)

No 10-Q data

Countries with THVT available (other)

No 10-Q data

Countries with THVT products available (other)

No 10-Q data

Countries with product sales (other)

No 10-Q data

Countries with transcatheter valves available (other)

No 10-Q data

Credit facilities available (other)

No 10-K data

Credit facilities borrowed (other)

No 10-K data

Credit facility availability (other)

No 10-K data

Credit facility capacity (other)

No 10-K data

Critical Care share of net sales (other)

No 10-Q data

Disposable pressure monitoring sales mix (other)

No 10-Q data

EVOLUTION II trial enrollment (other)

No 10-K data

Effective income tax rate (other)

No 10-K data

Effective tax rate (other)

No 10-K data

FX forward notional (other)

No 10-K data

Foreign Patent Applications (other)

No 10-Q data

Foreign Patents (other)

No 10-Q data

Foreign currency forward notional (other)

No 10-K data

Forward currency agreement notional (other)

No 10-K data

Fund net asset value (other)

No 10-K data

Geographic share of net sales (other)

No 10-Q data

Gross margin (other)

No 10-K data

Gross margin uplift from FX hedging (other)

No 10-K data

Gross profit margin (other)

No 10-K data

Gross profit percentage (other)

No 10-K data

Hemodynamic monitoring share of net sales (other)

No 10-Q data

Interest rate swap notional (other)

No 10-K data

Interest rate swap notional amount (other)

No 10-K data

International net sales mix (other)

No 10-Q data

International sales mix (other)

No 10-Q data

International sales share (other)

No 10-Q data

International share of net sales (other)

No 10-Q data

Issued Foreign Patents (other)

No 10-Q data

Issued US Patents (other)

No 10-Q data

Issued US patents (other)

No 10-Q data

Issued United States patents (other)

No 10-Q data

Issued foreign patents (other)

No 10-Q data

Long-lived tangible assets (other)

Net sales growth rate (other)

No 10-K data

Net sales mix by geography (other)

No 10-Q data

Net sales mix by product (other)

No 10-Q data

Net sales mix by product category (other)

No 10-Q data

Net sales mix by product group (other)

No 10-Q data

Net sales mix outside the United States (other)

No 10-Q data

Net sales mix — United States (other)

No 10-Q data

Net sales mix — outside United States (other)

No 10-Q data

Nonvested restricted stock units (other)

No 10-K data

Number of Reportable Segments (other)

Option-based product notional (other)

No 10-K data

PARTNER trial enrollment (other)

No 10-K data

Patent portfolio (other)

No 10-Q data

Patents (other)

No 10-Q data

Patents and applications owned (other)

No 10-Q data

Patents and patent applications (other)

No 10-Q data

Patients treated (other)

No 10-Q data

Pending Foreign Patent Applications (other)

No 10-Q data

Pending US Patent Applications (other)

No 10-Q data

Planned workforce reduction (other)

No 10-K data

Product group share of net sales (other)

No 10-Q data

R&D as % of net sales (other)

R&D as percent of net sales (other)

No 10-Q data

R&D as percentage of net sales (other)

R&D expense as percent of net sales (other)

No 10-Q data

R&D expense ratio (other)

R&D investment (other)

R&D investment intensity (other)

No 10-K data

R&D investment rate (other)

No 10-K data

R&D investment ratio (other)

R&D percent of net sales (other)

No 10-K data

R&D percent of sales (other)

No 10-K data

R&D percentage of net sales (other)

No 10-K data

Remaining repurchase authority (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining service period (other)

No 10-K data

Remaining share repurchase authority (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Remaining stock compensation cost (other)

No 10-K data

Remaining stock-based compensation cost (other)

No 10-K data

Repurchase authorization remaining (other)

No 10-K data

Research and Development Expense (other)

No 10-Q data

Research and development expense (other)

Research and development expense ratio (other)

No 10-K data

Research and development intensity (other)

No 10-Q data

Research and development investment (other)

No 10-Q data

Research and development spending (other)

No 10-Q data

Restricted stock units nonvested (other)

No 10-K data

Restricted stock units outstanding (other)

No 10-K data

Revenue mix by geography (other)

No 10-Q data

Revolving credit borrowings outstanding (other)

No 10-K data

Revolving credit facilities borrowed (other)

No 10-K data

Rule 10b5-1 plan availability (other)

No 10-K data

SG&A expense ratio (other)

No 10-K data

SG&A percent of net sales (other)

No 10-K data

SG&A percentage of net sales (other)

No 10-K data

Sales outside United States (other)

No 10-Q data

Selling, general and administrative expense ratio (other)

No 10-K data

Share of net sales (other)

No 10-Q data

Shares outstanding (other)

No 10-K data

Shares repurchased (other)

Shares reserved for equity awards (other)

No 10-Q data

Stock options exercisable (other)

No 10-K data

Stock options granted (other)

No 10-K data

Stock options outstanding (other)

No 10-K data

Stock repurchase authorization remaining (other)

No 10-K data

Stockholders of Record (other)

No 10-Q data

Stockholders of record (other)

No 10-Q data

Surgical heart valve share of net sales (other)

No 10-Q data

Surgical share of net sales (other)

No 10-Q data

Surgical tissue heart valve sales mix (other)

No 10-Q data

Surgical tissue valve share of net sales (other)

No 10-Q data

TAVR share of net sales (other)

No 10-Q data

Trade receivables sold under securitization (other)

No 10-K data

Transcatheter heart valve sales mix (other)

No 10-Q data

Transcatheter heart valve share of net sales (other)

No 10-Q data

Transcatheter share of net sales (other)

No 10-Q data

Treasury shares (other)

No 10-K data

Treasury shares held (other)

No 10-K data

Treasury shares outstanding (other)

No 10-K data

Treasury shares repurchased (other)

No 10-K data

Treasury shares retired (other)

No 10-K data

U.S. share of net sales (other)

No 10-Q data

US Patent Applications (other)

No 10-Q data

US Patents (other)

No 10-Q data

Uncertain tax position liability (other)

No 10-K data

United States share of net sales (other)

No 10-Q data

Unrecognized stock compensation (other)

No 10-K data

Unrecognized stock compensation cost (other)

No 10-K data

Unrecognized stock compensation expense (other)

No 10-K data

Unrecognized tax position liability (other)

No 10-K data

Unvested equity award compensation cost (other)

No 10-K data

Unvested equity award cost (other)

No 10-K data

Weighted average basic shares (other)

No 10-K data

Weighted average diluted shares (other)

No 10-K data

Weighted-average diluted shares (other)

No 10-K data

PARTNER trial enrollment (patients)

Open heart surgeries — Congenital (procedures)

Catheters and monitors sold (units_shipped)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data

Demographics

No demographic data found.

Workforce Breakdowns

No 10-K data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringin_progress2025-12USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for realignment initiatives recorded December 2025; liability roll-forward shows $13.3M at 2025-12-31, $3.5M of payments in 1H2026, $9.8M remaining at 2026-06-30. No employee count, geography, or completion date disclosed.
2026-06-30restructuringin_progress2025-12-01USD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expense recorded in Dec 2025 related to severance associated with realignment initiatives. Liability balance was $9.8 million as of June 30, 2026. Employee count not disclosed.
2026-03-31restructuringin_progress2025-12Realignment initiativesUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance expense for realignment initiatives was recorded in December 2025; liability rolled from $13.3M to $11.4M during Q1 2026 via $1.9M of payments. No employee counts, geography, or completion date disclosed.
2026-03-31acquisition_additioncompleted2026-02-062026-02-06U.S. segment — Autus Valve Technologies, Inc.business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Option exercised to acquire Autus for $128.9M total consideration; acquired workforce not quantified in the filing.
2026-03-31restructuringin_progress2025-12-01USD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expense recorded in Dec 2025 related to severance associated with realignment initiatives. Liability balance was $11.4M at Mar 31, 2026.
2026-03-31acquisition_additioncompleted2026-02-06USD 129 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Autus Valve Technologies, Inc. for total consideration of $128.9M. Headcount not disclosed.
2025-12-31restructuringin_progress2025-12-31Not specifiedNot specifiedUSD 13 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance expense recorded in December 2025 for a realignment initiative; employee count not disclosed. Restructuring liability balance was $13.3M at 2025-12-31 after $19.9M of payments during the year.
2025-12-31divestiture_reductioncompleted2025-12-182025-12-18Not specifiedNon-core product group (discontinued operations)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of the non-core product group completed 2025-12-18 for $81.8M up-front consideration; headcount removed through the disposition not disclosed. Classified as held-for-sale in September 2024.
2025-12-31acquisition_additionannounced2026-02-282026-02-28Not specifiedMedical device company (unnamed)USD 38 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		February 2026 acquisition for $38.0M cash plus up to $132.5M contingent consideration; exact date within February 2026 not specified. Headcount added not disclosed.
2025-12-31restructuringcompleted2025-12-01GlobalVariousUSD 13 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Expense of $13.1 million recorded in December 2025 related to severance associated with a realignment initiative. Employee count not disclosed.
2025-12-31restructuringcompleted3602024-09GlobalUSD 33 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Global workforce realignment impacting approximately 360 employees. Charge recorded in September 2024.
2025-12-31restructuringcompleted2025-12USD 13 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance associated with a realignment initiative. Employee count not disclosed.
2025-12-31restructuringin_progressUSD 13,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progress2%2024-092025-12-31GlobalGlobal workforceUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global workforce realignment announced September 2024 affecting approximately 2% of employees; no absolute headcount given. Restructuring liability was $6.6M at 2025-09-30 after $13.5M of payments in the nine months; remaining severance expected substantially paid by end of 2025. No new restructuring charges recorded in Q3 2025 ($0.1M in the quarter, $8.5M YTD, primarily advisory costs for the Critical Care sale).
2025-09-30restructuringin_progress2%2024-09-012025-12-31GlobalGlobal workforce realignmentUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting approximately 2% of employees. Remaining severance obligations expected to be substantially paid by end of 2025.
2025-09-30divestiture_reductioncompleted2024-06-032024-09-03GlobalCritical Care product groupdiscontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Critical Care to Becton, Dickinson and Company completed. Headcount removed not explicitly quantified.
2025-09-30divestiture_reductionannounced2025-10-012025-12-31GlobalNon-core product groupsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Definitive agreement entered in October 2025 to sell non-core product group. Transaction expected to close in Q4 2025.
2025-09-30restructuringin_progressUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progress2%2024-092025-12-31GlobalNot specifiedUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global workforce realignment recorded September 2024 affecting approximately 2% of employees; no absolute headcount given. Restructuring liability rolled from $20.1M (2024-12-31) to $10.3M (2025-06-30) after $9.8M of payments; remaining severance expected to be substantially paid in H2 2025. No restructuring expense recorded in the six months ended 2025-06-30.
2025-06-30divestiture_reductionannounced2024-092025Not specifiedNon-core product groupother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company committed to a plan to sell a small non-core product group (held-for-sale since September 2024), with sale expected during 2025; no headcount associated with the divestiture is disclosed.
2025-06-30restructuringin_progress2%2024-09-012025-12-31GlobalGlobal workforce realignmentUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting approximately 2% of employees. Remaining severance obligations expected to be substantially paid in the second half of 2025.
2025-03-31restructuringin_progress2%2024-09GlobalCompany-wideUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global workforce realignment recorded September 2024, primarily severance, affecting approximately 2% of employees; no absolute headcount given. Restructuring liability roll-forward: $20.1M at 2024-12-31, $6.1M payments in Q1 2025, $14.0M at 2025-03-31. Remaining severance obligations expected to be substantially paid within 12 months of 2025-03-31.
2025-03-31restructuringin_progress2%2024-09-012026-03-31GlobalAll functionsUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting approximately 2% of employees. Remaining obligations expected to be substantially paid within 12 months.
2024-12-31restructuringin_progress3602024-09-30GlobalGlobal workforce realignmentUSD 33 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Expense recorded in September 2024; $20.1M of remaining severance obligations expected to be substantially paid within 12 months of year-end
2024-12-31divestiture_reductioncompleted2024-06-032024-09-03GlobalCritical Care product groupdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Critical Care to Becton, Dickinson and Company for $4.2 billion closed September 3, 2024; associated headcount transferred not quantified. $19.0M of advisory costs recorded in Q4 2024
2024-12-31acquisition_additioncompleted2024-07-222024-07-22Not disclosedTAVR (aortic regurgitation technology)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase consideration $116.3M net of cash acquired; acquired headcount not disclosed
2024-12-31acquisition_additioncompleted2024-08-192024-08-19United StatesHeart failure management (implantable sensor)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase consideration $798.8M net of cash acquired; acquired headcount not disclosed
2024-12-31acquisition_additioncompleted2024-10-012024-10-01Rest of World segmentTranscatheter mitral valve replacementbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase consideration $380.9M net of cash acquired; acquired headcount not disclosed
2024-12-31divestiture_reductionannounced2024-12-312025-12-31Not disclosedNon-core product groupMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company committed to a plan to sell a non-core product group, with sale expected during 2025; classified as held-for-sale in September 2024 and included in discontinued operations; headcount not quantified
2024-12-31restructuringcompleted3602024-092025-12-31GlobalUSD 33 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global workforce realignment impacting approximately 360 employees. Remaining severance obligations of $20.1 million expected to be substantially paid within the next 12 months.
2024-12-31restructuringin_progress3602024-09-012025-12-31GlobalUSD 33 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Global workforce realignment impacting approximately 360 employees. Remaining severance obligations of $20.1 million expected to be substantially paid within the next 12 months.
2024-12-31divestiture_reductioncompleted2024-06-032024-09-03GlobalCritical CareUSD 19 (millions)discontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of Critical Care product group to Becton, Dickinson and Company. Headcount removed not explicitly disclosed.
2024-12-31restructuringin_progressUSD 32,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progress3602024-092025-09-30GlobalUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global workforce realignment recorded September 2024; charge primarily severance. Remaining severance obligations of $30.6M expected to be substantially paid within 12 months of quarter-end. Filer does not disclose total headcount, so affected-percent cannot be computed.
2024-09-30restructuringin_progress3602024-09-302025-09-30GlobalUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting approximately 360 employees. Remaining severance obligations of $30.6 million expected to be substantially paid within the next 12 months.
2024-09-30restructuringin_progress360USD 32,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2024-09-30restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 32,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30divestiture_reductionin_progress2024-06-032024-09-30GlobalCritical Care product groupother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell Critical Care to Becton, Dickinson and Company for $4.2 billion; headcount affected not disclosed. Separation costs of $121.0M for six months ended June 30, 2024 recorded in discontinued operations.
2024-06-30acquisition_additionannounced2024-07-01United StatesJenaValve Technology, Inc.USD 500 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire JenaValve for $500.0M cash plus up to $445.0M in milestones; headcount not disclosed.
2024-06-30acquisition_additionannounced2024-07-01United StatesEndotronix, Inc.USD 600 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Endotronix for $600.0M cash plus $75.0M milestones; headcount not disclosed.
2024-06-30acquisition_additionannounced2024-07-01IsraelInnovalve Bio Medical LimitedUSD 300 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Innovalve for $300.0M cash plus $25.0M regulatory milestone; headcount not disclosed.
2024-06-30acquisition_additionannounced2024-07-01Early-stage medical device company (catheter-based valvular disease treatment)USD 115 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Paid $115.0M ($5.0M in May 2024, $110.0M in July 2024) with up to $200.0M sales milestones; headcount not disclosed.
2024-06-30divestiture_reductionannounced2024-06-032024-09-30GlobalCritical CareUSD 121 (millions)discontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement to sell Critical Care product group to Becton, Dickinson and Company for $4.2 billion. Separation costs of $121.0 million recorded for six months ended June 30, 2024, primarily for consulting, legal, tax, and advisory services. Employee count not disclosed.
2024-03-31divestiture_reductionannounced2023-12-072024-12-31GlobalCritical Care product groupUSD 41 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned tax-free spin-off of Critical Care as a separate public company; $41.3M separation costs in Q1 2024 for consulting, legal, tax, and advisory services. No employee count disclosed.
2023-12-31divestiture_reductionannounced2023-12-072024-12-31GlobalCritical CareUSD 17 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Critical Care product group announced 2023-12-07, expected around end of 2024; $17.2M charge for consulting, legal, tax, and advisory costs. Headcount to be separated not disclosed.
2023-12-31acquisition_additioncompleted2023-02-282023-02-28Rest of WorldOtherbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 61% of a medical technology company on 2023-02-28, consolidated as a VIE; headcount added through the acquisition not disclosed
2023-12-31restructuringcompleted2022-09United StatesSurgical Structural HeartUSD 62 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Exit of HARPOON surgical mitral repair system program. Charge primarily related to full impairment of intangible assets ($52.7M) and other exit costs. No specific employee count disclosed.
2023-12-31restructuringin_progress2023-12-072024-12-31GlobalCritical CareUSD 17 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced tax-free spin-off of Critical Care product group. Charge related to consulting, legal, tax, and professional advisory services. Spin-off expected around end of 2024.
2023-06-30acquisition_additioncompleted2023-02-28Rest of World segment (goodwill assigned)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 61% of a medical technology company (consolidated as VIE); no employee headcount added or retained disclosed in the filing.
2023-03-31acquisition_additioncompleted2023-02-28Rest of World segment (goodwill assigned)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 61% of a medical technology company and consolidated it as the primary beneficiary of a VIE; no employee headcount disclosed for the acquired entity.
2022-12-31restructuringcompleted2022-09-302022-12-31United StatesSurgical Structural Heart (HARPOON surgical mitral repair system program)USD 62 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		In September 2022 the Company decided to exit the HARPOON program, recording a $62.3M charge to its U.S. segment ($60.7M in Special Charge, $1.6M in Cost of Sales), primarily a $52.7M full impairment of associated intangible assets plus other exit costs; no employees-affected count disclosed. An $11.7M contingent consideration gain was also recorded.
2022-12-31restructuringcompleted2022-09-01United StatesSurgical Structural HeartUSD 61 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company decided to exit its HARPOON surgical mitral repair system program in September 2022. Recorded a $60.7 million special charge primarily related to impairment of intangible assets. No specific employee count disclosed.
2022-09-30restructuringcompleted2022-09-30United StatesUnited States segment — HARPOON surgical mitral repair system programUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program exit decided September 2022; charge primarily full impairment of intangible assets plus other exit costs ($66.8M in Special Charge, $1.6M in Cost of Sales). No employee count or severance amount disclosed; an $11.7M contingent consideration gain was recorded on the exit.
2019-12-31acquisition_additioncompleted2019-02-112019-04-18United StatesCritical Carebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CASMED closed 2019-04-18 for a cash purchase price of $100.8 million; acquired headcount not disclosed. Acquisition-related costs of $2.0 million recorded in SG&A.
2019-12-31plant_closurecompleted2322017-092019-12-31SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of the Horw, Switzerland manufacturing plant. Severance charge of $10.2 million impacting 232 employees was recorded in September 2017 (prior-year program); the filing states payments related to the realignment were complete as of 2019-12-31. A related $7.1 million curtailment gain was recorded in 2018.
2019-12-31restructuringcompleted2322017-09-012019-12-31SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Planned closure of manufacturing plant in Switzerland. Payments related to the realignment were complete as of December 31, 2019.
2019-12-31acquisition_additioncompleted2019-04-182019-04-18GlobalCritical CareUSD 101 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of CAS Medical Systems, Inc. (CASMED) completed on April 18, 2019. Headcount not explicitly disclosed.
2019-06-30acquisition_additioncompleted2019-02-112019-04-18United StatesCritical Carebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CAS Medical Systems, Inc. closed 2019-04-18 for $100.8 million cash; no employee headcount added disclosed. Acquisition-related costs of $2.0 million recorded in SG&A.
2019-03-31acquisition_additioncompleted2019-02-112019-04-18United StatesCritical CareUSD 100 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement signed 2019-02-11; closed 2019-04-18 at $2.45/share (~$100M equity value). Headcount added not disclosed; charge value is purchase price, not a workforce charge. Company plans to integrate acquired tissue-oxygenation monitoring technology into its hemodynamic monitoring platform.
2018-12-31plant_closurecompleted2322017-092018-12-31SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced with a $10.2M severance charge in September 2017 affecting 232 employees; in March 2018 the company recorded a $7.1M gain from curtailment of the Swiss defined benefit plan. Payments related to the realignment were substantially complete as of December 31, 2018. Charge amount shown is the 2017 program charge disclosed in this filing.
2018-12-31acquisition_additionannounced2019-02-11United StatesCritical Caresubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire CAS Medical Systems for $2.45 per share (~$100M equity value); headcount added not disclosed. Announced after fiscal year-end but before the filing date.
2018-12-31restructuringcompleted2322017-09-012018-12-31SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charge recorded in September 2017 related to planned closure of manufacturing plant in Switzerland. Payments substantially complete as of December 31, 2018.
2018-09-30plant_closurein_progress2322017-092019-03-31SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded September 2017 for planned closure of the Switzerland manufacturing plant, primarily severance for 232 employees plus other costs. As of 2018-09-30, remaining severance obligations of $0.8 million expected to be substantially paid by 2019-03-31. A $7.1 million curtailment gain on the Swiss defined benefit plan was recorded in March 2018 in connection with the closure.
2018-09-30plant_closurecompleted2322017-09-012019-03-31SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in Sept 2017 for closure of manufacturing plant; remaining severance obligations of $0.8 million expected to be substantially paid by March 31, 2019.
2018-09-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSegment Reconciling Items [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30plant_closurein_progress2322017-092018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded September 2017 for planned closure of Swiss manufacturing plant, primarily severance for 232 employees. Remaining severance obligations of $1.4 million expected to be substantially paid by 2018-09-30. A $7.1 million gain from curtailment of the Swiss defined benefit plan related to the same closure was recorded in March 2018.
2018-06-30plant_closurein_progress2322017-09-012018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in Sept 2017 for closure of manufacturing plant; remaining severance obligations of $1.4 million expected to be substantially paid by Sept 30, 2018.
2018-03-31plant_closurein_progress2322017-09-302018-09-30SwitzerlandManufacturingUSD 10 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded September 2017 for planned closure of Swiss manufacturing plant; remaining severance obligations of $1.8 million expected substantially paid by 2018-09-30. A $7.1 million curtailment gain on the Swiss defined benefit plan was recorded in March 2018.
2018-03-31plant_closurein_progress2322017-09-012018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in Sept 2017 primarily for severance impacting 232 employees and other costs associated with planned closure of manufacturing plant. Remaining severance obligations of $1.8 million expected to be substantially paid by Sept 30, 2018.
2017-12-31plant_closurein_progress2322017-09-302018-09-30SwitzerlandHeart valve manufacturingUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge primarily severance for 232 employees plus other costs for planned closure of the Switzerland manufacturing plant; remaining severance obligations of $9.6 million expected to be substantially paid by 2018-09-30. Company announced the discontinuation of Switzerland heart valve manufacturing operations in September 2017, effective early 2018.
2017-12-31acquisition_additioncompleted2017-12-012017-12-01United StatesSurgical Heart Valve Therapy (mitral repair)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Harpoon Medical closed 2017-12-01 for $119.5 million cash plus up to $150.0 million in milestone payments; no employee count disclosed for the acquired workforce.
2017-12-31acquisition_additioncompleted2017-01-232017-01-23IsraelTranscatheter Heart Valve Therapy (mitral/tricuspid repair)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed 2017-01-23; consideration included ~2.8 million shares (fair value $266.5 million) and $86.2 million cash, plus up to $350.0 million contingent milestones; no employee count disclosed for the acquired workforce.
2017-12-31restructuringcompleted2322017-092018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charge related primarily to severance expenses impacting 232 employees and other costs associated with the planned closure of manufacturing plant in Switzerland. Remaining severance obligations of $9.6 million expected to be substantially paid by September 30, 2018.
2017-12-31restructuringin_progress2322017-092018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge related primarily to severance expenses and other costs associated with the planned closure of its manufacturing plant in Switzerland. Remaining severance obligations of $9.6 million expected to be substantially paid by September 30, 2018.
2017-09-30plant_closurein_progress2322017-092018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge related primarily to severance for 232 employees plus other costs tied to the planned closure of the Switzerland manufacturing plant; remaining severance obligations of $9.6 million expected to be substantially paid by 2018-09-30. Also referenced in MD&A Special Charges discussion; extracted once from the footnote.
2017-09-30acquisition_additioncompleted2016-11-262017-01-23Rest of World segment (goodwill assigned)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Valtech Cardio Ltd. acquisition closed 2017-01-23; filing does not disclose headcount added. Consideration included approximately 2.8 million shares (fair value $266.5 million) and $86.2 million cash.
2017-09-30restructuringin_progress2322017-09-302018-09-30SwitzerlandManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge related primarily to severance expenses and other costs associated with the planned closure of its manufacturing plant in Switzerland.
2017-09-30restructuringin_progress232Facility Closing [Member]USD 10,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2016-12-31acquisition_additioncompleted2016-11-262017-01-23IsraelTranscatheter Heart Valve Therapybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement signed 2016-11-26; transaction closed 2017-01-23 (subsequent to fiscal year-end). Consideration of approximately $340.0 million in stock and cash, plus up to $350.0 million in milestone payments over 10 years. Headcount added not disclosed. Acquisition-related costs of $4.1 million recorded in SG&A during 2016.
2016-12-31otherannounced2017-01-23IsraelTranscatheter Heart Valve Therapybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Concurrent with the Valtech closing, the Company entered an exclusive option to acquire the spun-off early-stage transseptal mitral valve replacement program for approximately $200.0 million; option expires two years after closing, extendable up to one year.
2015-12-31acquisition_additioncompleted2015-07-032015-08-26United StatesTranscatheter Heart Valve Therapy (mitral valve program)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement signed 2015-07-03; closed 2015-08-26 for $348.0 million cash plus a contingent $50.0 million milestone payment. Headcount added through the acquisition is not disclosed.
2015-12-31acquisition_additioncompleted2015-07-032015-08-26GlobalTranscatheter Heart Valve TherapyUSD 348 (millions)Note 7 — Acquisition
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of CardiAQ Valve Technologies, Inc. closed August 26, 2015. Specific headcount added not disclosed.
2015-12-31acquisition_additioncompleted2015-07-032015-08-26GlobalTranscatheter Heart Valve TherapyUSD 348 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of CardiAQ Valve Technologies, Inc. closed August 26, 2015. Headcount not explicitly disclosed.
2015-12-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30acquisition_additioncompleted2015-07-032015-08-26United StatesUnited States segment — transcatheter mitral valve programUSD 1 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger closed 2015-08-26 for $348.0M cash plus contingent $50.0M milestone; acquisition-related costs of $1.2M recorded in SG&A. Headcount added not disclosed. Exhibit 10.1 indicates certain CardiAQ personnel became employees effective 2015-09-01, count not stated.
2015-09-30restructuringcompleted2014-09-01United StatesAutomated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Prior-year (Sept 2014) refocus of automated glucose monitoring resources, including severance; disclosed here only as comparative context for the zero special charges in the current nine-month period. No employee count given.
2015-09-30restructuringcompleted2014-09-01Automated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in Sept 2014 for strategic shift; includes severance costs. No employee count disclosed.
2014-12-31restructuringcompleted2014-09-30Not specifiedCritical Care — automated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		September 2014 strategic refocus discontinued the automated glucose monitoring program; charge covered intangible and fixed asset write-downs plus severance costs. Number of employees affected not disclosed. A separate $2.0 million charge to Cost of Sales related to disposal of customer-held inventory and equipment.
2014-12-31restructuringcompleted1182013-12-012015-12-31GlobalUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global workforce realignment impacting 118 employees. Charge recorded in December 2013. Remaining severance obligations of $3.3 million expected to be substantially paid by end of 2015.
2014-12-31restructuringcompleted922012-12-012014-12-31GlobalUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global workforce realignment impacting 92 employees. Charge recorded in December 2012. Payments related to the realignment were complete as of December 31, 2014.
2014-12-31restructuringcompleted2014-09-012014-09-30Automated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Strategic shift to discontinue automated glucose monitoring program. Charge includes write-down of intangible asset and fixed assets, and severance costs. Employee count not explicitly disclosed.
2014-12-31restructuringcompleted1182013-122015-12-31GlobalGlobal workforce realignmentUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge recorded in Dec 2013 for global workforce realignment impacting 118 employees. Remaining severance obligations of $3.3 million expected to be substantially paid by end of 2015.
2014-12-31restructuringcompleted922012-122014-12-31GlobalGlobal workforce realignmentUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge recorded in Dec 2012 for global workforce realignment impacting 92 employees. Payments related to the realignment were complete as of Dec 31, 2014.
2014-12-31restructuringcompleted2014-092014-09GlobalAutomated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Strategic shift to discontinue automated glucose monitoring program. Charge includes write-down of intangible/fixed assets and severance costs. Employee count not explicitly disclosed.
2014-09-30restructuringcompleted2014-09Automated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Refocus of resources away from automated glucose monitoring; charge covered intangible and fixed asset write-downs plus severance. A separate $2.0M charge to Cost of Sales related to disposal of customer-held inventory and equipment. No employee count disclosed.
2014-09-30restructuringcompleted2014-09-30Automated glucose monitoring programUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Refocus resources from automated glucose monitoring program; charge includes write-down of intangible/fixed assets and severance costs.
2013-12-31restructuringin_progress1182013-122014-12-31GlobalGlobal workforce realignmentUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recorded December 2013, primarily severance; remaining severance obligations of $9.2 million expected to be substantially paid by end of 2014
2013-12-31restructuringcompleted1182013-12-012014-12-31GlobalGlobal workforce realignmentUSD 10 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2013 global workforce realignment impacting 118 employees. $10.4 million charge recorded primarily for severance. Remaining obligations of $9.2 million expected to be substantially paid by end of 2014.
2013-12-31restructuringin_progress1182013-12-012014-12-31GlobalUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 118 employees. Remaining severance obligations of $9.2 million expected to be substantially paid by end of 2014.
2013-12-31restructuringin_progressUSD 10,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress2013 global workforce realignmentUSD 10,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress1182013 global workforce realignment / Employee Severance [Member]USD 10,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress922012-122013-12-31GlobalGlobal workforce realignmentUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recorded December 2012, primarily severance; remaining severance obligations of $8.5 million expected to be substantially paid by end of 2013.
2012-12-31acquisition_additioncompleted2012-10-092012-10-09NetherlandsCritical Care (non-invasive hemodynamic monitoring)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding shares for €28.4 million ($36.9 million); acquired headcount not disclosed.
2012-12-31restructuringcompleted922012-12-012013-12-31GlobalUSD 9 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global workforce realignment impacting 92 employees. $9.0 million charge recorded in December 2012. Remaining severance obligations of $8.5 million expected to be substantially paid by end of 2013.
2012-12-31restructuringin_progress922012-12-012013-12-31GlobalUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 92 employees. Remaining severance obligations of $8.5 million expected to be substantially paid by end of 2013.
2012-12-31restructuringin_progress92 Restructuring Charges / Employee Severance2012 Realignmentrestructuring_footnote
f5-10k / no-ai-xblr
2012-09-30acquisition_additionannounced2012-10-092012-10-09NetherlandsCritical Care / hemodynamic monitoringUSD 42 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of BMEYE, B.V. for EUR 32.5 million (approx. $42 million); purchase price primarily goodwill and IPR&D. No employee count disclosed.
2011-12-31restructuringin_progress492011-122013-03-31GlobalNot specifiedUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recorded December 2011, primarily severance for a global workforce realignment; remaining severance obligations of $5.2 million expected to be substantially paid by March 2013. A prior-year realignment affecting 84 employees (December 2010, $7.2 million) is excluded as it falls outside the current fiscal year.
2011-12-31acquisition_additioncompleted2011-03-112011-03-11Not specifiedEurope segment (goodwill assigned)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All outstanding shares acquired for $42.6 million cash; Embrella was a start-up developing a cerebral embolic protection device. No employee headcount added is disclosed.
2011-12-31divestiture_reductioncompleted2011-03-312011-03-31Not specifiedVascularMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company discontinued distribution of artificial implantable grafts during the first quarter of 2011, contributing to a $2.3 million decline in Vascular net sales. No associated headcount reduction is disclosed.
2011-12-31restructuringcompleted492011-12-012013-03-31GlobalGlobal workforce realignmentUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2011 global workforce realignment impacting 49 employees. Charge of $5.5 million primarily for severance. Remaining obligations of $5.2 million expected to be substantially paid by March 2013.
2011-12-31restructuringcompleted842010-12-012012-06-30GlobalGlobal workforce realignmentUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2010 global workforce realignment impacting 84 employees. Charge of $7.2 million primarily for severance. As of Dec 31, 2011, remaining obligations of $1.2 million expected to be substantially paid by June 2012.
2011-12-31restructuringin_progress492011-12-312013-03-31GlobalUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 49 employees. Remaining severance obligations of $5.2 million expected to be substantially paid by March 2013.
2011-12-31restructuringin_progress49 Restructuring Charges / Employee Severance2011 Realignmentrestructuring_footnote
f5-10k / no-ai-xblr
2011-09-30restructuringin_progress842010-122012-03GlobalGlobal workforce realignmentUSD 7 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded December 2010, primarily severance for 84 employees; $1.5M of remaining severance obligations expected to be substantially paid by March 2012 as of September 30, 2011.
2011-09-30acquisition_additioncompleted2011-03-11Europe segment (goodwill assigned); cerebral embolic protection device developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding shares for $42.6M cash; headcount added through the acquisition is not disclosed in this filing.
2011-09-30restructuringin_progress842010-12-012012-03-31GlobalUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 84 employees; remaining severance obligations of $1.5 million expected to be substantially paid by March 2012.
2011-06-30restructuringin_progress842010-122011-12GlobalUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global workforce realignment announced December 2010, primarily severance, impacting 84 employees. As of 2011-06-30 remaining severance obligations of $1.9 million expected to be substantially paid by December 2011. Charge recorded in December 2010 (prior fiscal year); no additional realignment charge in the current quarter.
2011-06-30acquisition_additioncompleted2011-03-11Cerebral embolic protection device developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All outstanding shares acquired for $42.6 million cash; headcount added through the acquisition is not disclosed. Acquisition-related costs of $0.9 million recorded in Other Income, net in Q1 2011.
2011-06-30restructuringin_progress842010-12-012011-12-31GlobalUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 84 employees; remaining severance obligations of $1.9 million expected to be substantially paid by December 2011.
2011-03-31restructuringin_progress842010-122011-12-31GlobalGlobal workforce realignmentUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded December 2010, primarily severance for 84 employees. Remaining severance obligations of $3.0 million as of 2011-03-31, expected to be substantially paid by December 2011. Also disclosed in MD&A under Special Charges.
2011-03-31restructuringin_progress842010-12-012011-12-31GlobalUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 84 employees; remaining severance obligations of $3.0 million expected to be substantially paid by December 2011.
2010-12-31restructuringcompleted842010-12-312011-12-31GlobalGlobal workforce realignmentUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recorded December 2010, primarily severance; remaining payments of $5.7 million expected to be paid in 2011. Announcement date approximated to charge-recording month (December 2010); exact announcement day not disclosed.
2010-12-31othercompleted2010-06-302010-06-30GlobalHeart Valve Therapy — MONARC transcatheter mitral valve programUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program discontinued in Q2 2010 due to slow enrollment in EVOLUTION II trial; $8.3M charge ($7.6M intangible impairment plus $0.7M clinical trial costs). No employee count disclosed; announcement date approximated to Q2 2010.
2010-12-31restructuringcompleted842010-12-312011-12-31GlobalUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global workforce realignment impacting 84 employees. Charge recorded in December 2010. Remaining payments of $5.7 million expected to be paid in 2011.
2010-12-31restructuringin_progress842010-12-012011-12-31GlobalUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Global workforce realignment impacting 84 employees. Charge recorded in December 2010 primarily for severance. Remaining payments of $5.7 million expected in 2011.
2009-12-31divestiture_reductioncompleted2009-06-302009-09-01Not disclosedCritical Care (hemofiltration product line)USD 2 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Hemofiltration product line sold effective 2009-09-01 for $55.9 million cash plus up to $9.0 million earn-out; $1.5 million charge recorded in June 2009 for transaction costs and employee severance related to the pending sale. No employee count disclosed.
2009-12-31divestiture_reductioncompleted2008-01-152009-09-30United StatesVascular (LifeStent product line)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		LifeStent sale occurred January 2008 (prior fiscal year); current-year event is the September 2009 transfer of device manufacturing to the buyer, which ended the Company's transition manufacturing obligations. Final $15.0 million milestone earned. No employee count disclosed.
2009-12-31restructuringcompleted2008-03-01GlobalExecutiveUSD 1 (millions)Item 7. MD&A - Special (Gains) Charges, net
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		March 2008 executive severance charge. Payments substantially complete as of Dec 31, 2009.
2009-12-31restructuringcompleted1802007-12-01United States, Europe, JapanGlobalUSD 14 (millions)Item 7. MD&A - Special (Gains) Charges, net
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2007 global reduction in workforce impacting approximately 180 employees, associated with LifeStent sale and termination of Japan distribution agreement. Payments substantially complete as of Dec 31, 2009.
2009-12-31restructuringcompleted1802007-122009-12-31United States, Europe, JapanGlobalUSD 14 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		December 2007 realignment expenses primarily related to severance associated with the sale of the LifeStent product line and a global reduction in workforce impacting approximately 180 employees. Payments substantially complete as of December 31, 2009.
2009-12-31restructuringcompleted2008-032009-12-31GlobalExecutiveUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		March 2008 charge for executive severance associated with business realignment. Payments substantially complete as of December 31, 2009.
2009-09-30restructuringcompleted1802007-12-012009-12-31United States, Europe, and JapanGlobal workforce reductionUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		December 2007 global reduction in workforce impacting approximately 180 employees. Remaining payments of approximately $1.3 million expected through end of 2009.
2009-09-30restructuringcompleted2008-03-012009-09-30GlobalExecutiveUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		March 2008 executive severance associated with business realignment. Payments substantially complete as of September 30, 2009.
2009-09-30divestiture_reductioncompleted2009-09-012009-09-01GlobalHemofiltration product lineUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of hemofiltration product line effective September 1, 2009. Includes $1.5 million charge in June 2009 for transaction costs and employee severance.
2009-06-30divestiture_reductionannounced2009-06Critical Care — hemofiltration product lineUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell hemofiltration assets for approximately $55.9 million plus up to $9.0 million contingent on buyer revenue objectives; the $1.5 million charge covers transaction costs and employee severance. Expected to close in Q3 2009 pending regulatory approvals; no employee count or geography disclosed.
2009-06-30restructuringin_progress2009-06-30GlobalHemofiltration product lineUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge for transaction costs and employee severance related to pending sale of hemofiltration assets. Employee count not disclosed.
2009-06-30restructuringcompleted2008-03-312009-12-31GlobalExecutive / CorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Executive severance associated with business realignment. Payments substantially complete as of June 30, 2009.
2009-06-30restructuringcompleted1802007-12-312009-12-31United States, Europe, JapanGlobal workforce reductionUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce impacting approximately 180 employees. Remaining payments of approx $1.7 million expected through end of 2009.
2009-03-31restructuringin_progress1802007-122009-12-31United States, Europe, JapanGlobalUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced December 2007; ~180 employees impacted at announcement. Remaining severance payments of approximately $2.1M expected through end of 2009. Also included termination of IABP distribution agreement in Japan.
2009-03-31divestiture_reductionin_progress2008-012010-06-30GlobalVascularother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		LifeStent peripheral vascular product line divested January 2008; no employee count disclosed. Company continues providing transition manufacturing services until mid-2010 or transfer of manufacturing to buyer. No headcount figure given.
2009-03-31restructuringin_progress1802007-12-012009-12-31United States, Europe, JapanGlobal workforce reductionUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		December 2007 realignment expenses primarily related to severance associated with LifeStent sale and global reduction in workforce impacting approximately 180 employees. Remaining payments of approximately $2.1 million expected through end of 2009.
2009-03-31restructuringin_progress2008-03-012009-12-31GlobalExecutiveUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		March 2008 charge for executive severance associated with business realignment. Remaining payments of $0.3 million expected through end of 2009.
2008-12-31divestiture_reductioncompleted2008-01-31United StatesVascularrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of the LifeStent peripheral vascular product line completed January 2008; no employee count disclosed. Company provides transition manufacturing services until mid-2010 or transfer of manufacturing to buyer.
2008-12-31restructuringcompleted2008-03-312009-12-31United StatesCorporateUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		March 2008 charge for executive severance tied to business realignment; remaining payments of $0.7 million expected through end of 2009. Number of executives affected not disclosed.
2008-12-31restructuringcompleted1802007-12-31United States, Europe, JapanGlobalUSD 14 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2007 realignment related to LifeStent sale and global workforce reduction. $3.0 million of accrued severance reversed in 2008. Remaining payments of $2.6 million expected in 2009.
2008-12-31restructuringcompleted922006-01-01JapanManufacturingUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		January 2006 realignment for planned closure of manufacturing facility in Japan. All payments complete as of December 31, 2008.
2008-12-31restructuringcompleted702006-12-31United States, EuropeGlobalUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2006 global reduction in workforce. All payments complete as of December 31, 2008.
2008-12-31restructuringcompleted2008-03-012009-12-31United StatesExecutiveUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		March 2008 executive severance associated with business realignment. Remaining payments of $0.7 million expected through end of 2009.
2008-12-31restructuringcompleted1802007-122009-12-31United States, Europe, JapanGlobalUSD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		December 2007 realignment related to LifeStent sale and global workforce reduction. $3.0 million reversed in 2008. Remaining payments of approx $2.6 million expected in 2009.
2008-12-31restructuringcompleted2008-032009-12-31GlobalExecutiveUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		March 2008 executive severance associated with business realignment. Remaining payments of $0.7 million expected through end of 2009.
2008-09-30restructuringin_progress1802007-122009-12-31United States, Europe and JapanGlobal realignment (LifeStent divestiture and intra-aortic balloon pump distribution termination)USD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced December 2007 (prior to this quarter) but disclosed as ongoing in this filing; approximately 180 employees impacted. Charge shown is remaining accrued severance payments expected through end of 2009; original $13.9M realignment charge was recorded in December 2007.
2008-09-30restructuringin_progress2008-032009-12-31Not specifiedExecutive severance tied to business realignmentUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Executive severance charge recorded March 2008, partly offset by a $1.4M reversal of December 2007 LifeStent-related accrued severance. Remaining payments of $1.0M expected through end of 2009. No employee count disclosed.
2008-09-30restructuringin_progress1802007-12-012009-12-31United States, Europe, JapanGlobalUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce impacting approximately 180 employees. Remaining payments of $3.4 million expected through end of 2009.
2008-09-30restructuringin_progress2008-03-012009-12-31GlobalExecutiveUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Executive severance associated with business realignment. Remaining payments of $1.0 million expected through end of 2009.
2008-06-30restructuringin_progress1802007-122008United States, Europe, JapanGlobal workforce (LifeStent divestiture and corporate realignment)USD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced December 2007; charge also covers termination of the intra-aortic balloon pump distribution agreement in Japan. Approximately 180 employees impacted; remaining severance payments of $5.0 million expected during 2008.
2008-06-30restructuringin_progress2008-032009ExecutiveUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Executive severance charge recorded March 2008 as part of the business realignment, partly offset by a $1.4 million reversal of severance accrued in Q4 2007 for the LifeStent sale. Remaining payments expected through the end of 2009; employee count not disclosed.
2008-06-30divestiture_reductioncompleted2008-01United StatesVascular (LifeStent peripheral vascular product line)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of LifeStent assets completed January 2008 with $74.0 million cash at closing plus up to $65.0 million in milestones; pre-tax loss of $8.1 million recorded. No headcount impact disclosed; company continues manufacturing for the buyer until mid-2010 or transfer of manufacturing.
2008-06-30restructuringin_progress1802007-12-012008-12-31United States, Europe, JapanGlobalUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce impacting approximately 180 employees. Remaining payments of $5.0 million expected in 2008.
2008-06-30restructuringin_progress2008-03-012009-12-31GlobalExecutiveUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Executive severance associated with business realignment. Remaining payments of $1.3 million expected through end of 2009.
2008-03-31restructuringin_progress1802007-122008United States, Europe and JapanGlobal — LifeStent product line sale and corporate realignmentUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance tied to LifeStent sale and workforce reduction of approximately 180 employees, plus termination of the Japan intra-aortic balloon pump distribution agreement; $8.9M of remaining payments expected during 2008. Q1 2008 realignment activity was a net $(0.1)M: $1.3M executive severance offset by a $1.4M reversal of prior-year LifeStent severance accrual.
2008-03-31divestiture_reductioncompleted2008-01GlobalVascular — LifeStent peripheral vascular product lineUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax loss on sale, not severance; no employee count disclosed. Company provides transition manufacturing services until mid-2010 or transfer of manufacturing to buyer, so workforce impact was not quantified and results were not reported as discontinued operations.
2008-03-31otherannounced22008-05-30United StatesExecutive management — Heart Valve and Cardiac Surgery Systems; Critical Care and Vascularother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Two Corporate Vice Presidents to separate on 2008-05-30 as part of an executive management reorganization; each receives $9,000/month for six months beginning 2009 plus $100,000 lump sums on 2009-03-01 and 2010-01-01 for transition services. Announcement date not stated in the filing.
2008-03-31restructuringin_progress1802007-12-012008-12-31United States, Europe, JapanUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce primarily in US, Europe, and Japan impacting approx 180 employees. Remaining payments of $8.9 million expected in 2008.
2008-03-31restructuringcompleted2008-03-012008-03-31ExecutiveUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Executive severance associated with business realignment, offset by $1.4 million reversal of previously accrued severance costs.
2007-12-31restructuringin_progress1802007-12-312008-12-31United States, Europe, JapanMultiple (includes LifeStent product line and corporate functions)USD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		December 2007 realignment charge covering severance tied to the LifeStent sale, a global workforce reduction of approximately 180 employees, and termination of the intra-aortic balloon pump distribution agreement in Japan; approximately $13.0 million of remaining payments expected during 2008.
2007-12-31acquisition_additioncompleted2007-12-312007-12-31Not disclosedCardiac Surgery Systems (minimally invasive heart valve surgery)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of certain assets of the CardioVations Division of Ethicon, Inc. completed December 2007 for a total purchase price of $28.1 million; no headcount acquired disclosed.
2007-12-31divestiture_reductioncompleted2008-01-31Not disclosedVascular (LifeStent peripheral vascular product line)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of LifeStent assets completed January 2008 for $74.0 million cash at closing plus up to $65.0 million in milestones; Company expects a pre-tax loss of approximately $7 million in Q1 2008, including a $34.6 million goodwill write-off. No headcount reduction disclosed; severance related to this sale is included in the December 2007 realignment charge.
2007-12-31restructuringin_progress1802007-12-312008-12-31United States, Europe, JapanGlobalUSD 14 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2007 realignment expenses related to sale of LifeStent product line and global workforce reduction. Remaining payments of approximately $13.0 million expected to be paid in 2008.
2007-12-31restructuringcompleted702006-12-312007-12-31United States, EuropeGlobalUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2006 global reduction in workforce. All payments substantially complete as of December 31, 2007.
2007-12-31restructuringcompleted922006-01-312007-12-31JapanManufacturingUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		January 2006 planned closure of manufacturing facility in Japan. All payments substantially complete as of December 31, 2007.
2007-12-31restructuringin_progress1802007-12-312008-12-31United States, Europe, JapanGlobalUSD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance expenses associated with the sale of the LifeStent product line and a global reduction in workforce. Remaining payments of approximately $13.0 million expected to be paid in 2008.
2007-12-31plant_closurecompleted922006-01-312006-12-31JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance expenses associated with the planned closure of a manufacturing facility in Japan. Recorded in January 2006. Payments substantially complete as of Dec 31, 2007.
2007-09-30reduction_in_forcein_progress702006-12-312007-12-31United States and EuropeUSD 7 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced in December 2006, prior to this quarter; disclosed here for ongoing severance payment status. Approximately $5.4 million of severance paid as of 2007-09-30, remainder expected substantially paid by end of 2007.
2007-09-30plant_closurein_progress922006-03-312007-12-31JapanManufacturingUSD 2 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned closure of a Japan manufacturing facility recorded in the first quarter of 2006 (announcement date approximated to quarter end); disclosed here for payment status. Remaining payments of about $0.4 million expected in Q4 2007.
2007-09-30restructuringcompleted522005-12-312007-09-30Puerto Rico, Europe and United StatesUSD 4 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Resource realignment charge recorded December 2005 (prior period); disclosed in this filing's special charges footnote. Related payments substantially complete as of 2007-09-30.
2007-09-30acquisition_additionannounced2007-11-012007-12-31CardioVations Division of Ethicon, Inc. — minimally invasive heart valve surgery products and technologyUSD 27 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire certain assets for approximately $27 million; no headcount transferred or affected was disclosed.
2007-09-30restructuringin_progress702006-12-012007-12-31United States and EuropeGlobal workforceUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce of approximately 70 employees. $5.4 million paid as of Sept 30, 2007; remainder expected substantially paid by end of 2007.
2007-09-30plant_closurein_progress922006-03-012007-12-31JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Planned closure of a manufacturing facility in Japan impacting 92 employees. Remaining payments of approx $0.4 million expected in Q4 2007.
2007-06-30restructuringin_progress702006-12-012007-12-31United States and EuropeUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce; $4.6 million paid as of June 30, 2007, with remainder expected substantially paid by end of 2007.
2007-06-30plant_closurein_progress922006-03-012007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Planned closure of manufacturing facility; remaining payments of approximately $1.3 million expected in Q3 2007.
2007-03-31plant_closurein_progress922006-03-312007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance tied to planned closure of a Japan manufacturing facility; announced in Q1 2006 (exact date not disclosed). $1.3 million paid as of 2007-03-31; payments expected through Q3 2007.
2007-03-31reduction_in_forcein_progress702006-12-312007-12-31United States; EuropeGlobalUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global reduction in workforce of approximately 70 employees recorded in December 2006 (month only; day not disclosed). $3.7 million of severance paid as of 2007-03-31; remainder expected substantially paid by end of 2007.
2007-03-31restructuringcompleted522005-12-312007-03-31Puerto Rico; Europe; United StatesGlobalUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Resource realignment recorded in December 2005 (month only; day not disclosed). Payments related to the realignment were substantially complete as of 2007-03-31.
2007-03-31restructuringin_progress922006-03-312007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Planned closure of manufacturing facility; $1.3M paid as of March 31, 2007.
2007-03-31restructuringin_progress702006-12-312007-12-31United States and EuropeGlobalUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global reduction in workforce; $3.7M paid as of March 31, 2007.
2006-12-31plant_closurein_progress922006-03-312007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		First-quarter 2006 charge related primarily to severance for the planned closure of a manufacturing facility in Japan; payments anticipated through the third quarter of 2007. Charge is net of a $0.4 million reversal of previously accrued severance from the Japan perfusion product line sale.
2006-12-31restructuringin_progress702006-12-312007-12-31United States and EuropeGlobalUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		December 2006 charge for severance tied to a global workforce reduction of approximately 70 employees; $0.4 million paid as of year-end, remainder expected to be paid substantially by end of 2007. Total realignment expenses, net for 2006 were $9.4 million.
2006-12-31restructuringcompleted702006-12-312007-12-31Global (primarily United States and Europe)USD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global reduction in workforce of approximately 70 employees. Charge of $7.3 million recorded in December 2006. Remaining amount expected to be paid out substantially by the end of 2007.
2006-12-31plant_closurein_progress922006-03-312007-09-30JapanManufacturingUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Planned closure of a manufacturing facility in Japan. Charge of $2.1 million recorded in the first quarter of 2006. Payments anticipated through the third quarter of 2007.
2006-12-31restructuringin_progress702006-12-312007-12-31United States and EuropeUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Global reduction in workforce of approximately 70 employees. Charge recorded in December 2006. Remaining amount expected to be paid out substantially by the end of 2007.
2006-12-31plant_closurein_progress922006-03-312007-09-30JapanManufacturingUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Planned closure of a manufacturing facility in Japan. Charge recorded in first quarter 2006. Payments anticipated through third quarter 2007.
2006-09-30plant_closurein_progress922006-03-312007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q1 2006 for planned closure of a Japan manufacturing facility affecting 92 employees; net of a $0.4M reversal of previously accrued severance. Payments expected through Q3 2007; $0.4M paid as of 2006-09-30. Announcement date shown as quarter-end of Q1 2006 because only the quarter of recording is disclosed.
2006-09-30divestiture_reductionin_progress2006-04-012006-12-31InternationalCardiopulmonary perfusion product lineUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of most assets of the remaining international cardiopulmonary perfusion product line initiated in Q2 2006; $2.6M impairment recorded (includes $1.5M direct incremental sale costs). No employee count disclosed. Announcement date shown as start of Q2 2006 because only the quarter is disclosed.
2006-09-30restructuringin_progress922006-01-012007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance expenses associated with the planned closure of a manufacturing facility in Japan. Payments anticipated through Q3 2007.
2006-06-30plant_closurein_progress922006-01-012007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Primarily severance for planned closure of a Japan manufacturing facility; $0.1M paid as of 2006-06-30; charge net of $0.4M reversal of prior severance accrual related to Terumo sale.
2006-06-30divestiture_reductioncompleted2006-05-01Not specifiedPharmaceutical product line (non-strategic)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of non-strategic pharmaceutical product line to Bioniche Teoranta for $9.0M with a $4.5M gain; no employee count disclosed.
2006-06-30divestiture_reductionin_progress2006-04-012006-12-31InternationalCardiopulmonary perfusion product lineUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Initiated sale of most remaining international perfusion assets; $2.6M impairment including $1.5M direct sale costs; carrying value $8.0M; no employee count disclosed.
2006-06-30restructuringin_progress922006-01-012007-09-30JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance expenses associated with planned closure of a manufacturing facility in Japan. Payments anticipated through Q3 2007.
2006-03-31plant_closurein_progress92JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Realignment charge recorded in Q1 2006 for planned closure of a Japan manufacturing facility affecting 92 employees; primarily severance expense, net of a $0.4M reversal of previously accrued severance. No severance payments had been made as of 2006-03-31. Announcement date and completion date not stated.
2006-03-31divestiture_reductioncompleted2005-01JapanCardiac Surgery Systems (perfusion products)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Japan perfusion products business to Terumo Corporation for $14.9M cash consideration ($9.2M received January 2005, $5.7M received March 2006); associated headcount not disclosed. Related exit of Japan pacemaker distribution business also part of the January 2005 Japan realignment.
2006-03-31plant_closurein_progress922006-03-31JapanManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Realignment expenses recorded in Q1 2006 for planned closure of a manufacturing facility. No severance payments made as of March 31, 2006.
2005-12-31restructuringin_progress522005-12-312006-12-31Puerto Rico, Europe, North AmericaResource realignment (cross-functional)USD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		December 2005 severance charge for a resource realignment reducing workforce by 52 employees; $1.3 million paid by year-end, remaining $2.6 million expected to be paid in 2006.
2005-12-31restructuringcompleted2005-01-312005-12-31JapanJapan operations — pacemaker distribution exit and perfusion products business realignmentUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		January 2005 Japan realignment: restructured operations, exited pacemaker distribution, and sold perfusion products business to Terumo; $5.7 million realignment charge (primarily severance from headcount reductions) plus $1.0 million pension settlement/curtailment charge, offset by $7.7 million gain on sale. Headcount reduction not quantified.
2005-12-31divestiture_reductioncompleted2005-11-302005-11-30Not disclosedVascular — vascular graft business (Lifespan product line)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Vascular graft business sold to Angiotech Pharmaceuticals for $14.0 million cash, resulting in a $13.1 million net gain; Company continues to market the Lifespan product line. Associated headcount not disclosed.
2005-12-31restructuringcompleted522005-12-012006-12-31Puerto Rico, Europe, North AmericaUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		December 2005 resource realignment. Charge of $3.9 million for severance costs associated with reducing workforce by 52 employees. $1.3 million paid as of Dec 31, 2005; remaining $2.6 million expected to be paid in 2006.
2005-12-31divestiture_reductioncompleted2005-01-012005-12-31JapanPerfusion productsUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		January 2005 realignment of Japan business. Exited pacemaker distribution and sold perfusion products business. $5.7 million charge related to realignment operations, primarily severance costs due to headcount reductions and pension settlement/curtailment.
2005-12-31restructuringcompleted522005-12-312006-12-31Puerto Rico, Europe, North AmericaUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Resource realignment in December 2005. Charge of $3.9 million related to severance for 52 employees. $1.3 million paid by year-end, $2.6 million expected to be paid in 2006.
2005-12-31restructuringcompleted2005-01-312006-12-31JapanPerfusion ProductsUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Realignment of operations in Japan in January 2005. Included exit from pacemaker distribution and sale of perfusion products business. $5.7 million charge primarily related to severance costs due to headcount reductions.
2005-09-30divestiture_reductionin_progress2005-012006-09-30JapanCardiac Surgery Systems (perfusion products); pacemaker distributionUSD 6 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Japan realignment: perfusion products business sold to Terumo, pacemaker distribution exited; $5.7M realignment charge mainly severance from headcount reductions. $2.8M severance paid through 2005-09-30, remainder due by 2006-09. Number of employees affected not disclosed.
2005-09-30divestiture_reductionannounced2005-11-032005-12-31Not disclosedVascular (vascular graft business)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell vascular graft business for approximately $14 million, subject to Board approval; expected close December 2005. Headcount impact not disclosed.
2005-09-30restructuringin_progress2005-01-012006-09-30JapanOperationsUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge related to realignment of operations, primarily severance costs due to headcount reductions. Remaining amount to be paid by September 2006.
2005-06-30restructuringin_progress2005-012006-09-30JapanPerfusion products, pacemaker distribution, and Japanese operationsUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Realignment of Japan operations announced January 2005; charge primarily severance from headcount reductions. $2.8M severance paid as of 2005-06-30, remainder due by September 2006. Number of employees affected not disclosed.
2005-06-30restructuringin_progress2005-012006-09JapanOperationsUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Realignment of Japanese operations including exit of pacemaker distribution business; charge primarily related to severance costs due to headcount reductions.
2005-03-31restructuringin_progress2005-012006-09-30JapanJapan operations (pacemaker distribution and related)USD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headcount reductions from severance-driven restructuring; number of employees affected not disclosed. $2.4M of severance paid as of 2005-03-31, remainder payable by September 2006.
2005-03-31divestiture_reductioncompleted2005-012006-12-31JapanCardiac Surgery Systems (perfusion products business)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Japan perfusion products business to Terumo Corporation; $9.2M received January 2005, recorded as a $7.7M gain. Headcount transferred not disclosed; business transition to buyer expected to complete in 2006.
2005-03-31restructuringin_progress2005-01-012006-09-30JapanJapanese operationsUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Realignment of business in Japan including exit of pacemaker distribution; charge primarily related to severance costs due to headcount reductions.
2004-12-31restructuringannounced602005-01-26JapanCardiopulmonary products and pacemaker distribution businessessubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Japan cardiopulmonary products business plus exit from pacemaker distribution in Japan will transfer or eliminate approximately 60 full-time positions; expected first-quarter 2005 charge of $6 million to $9 million (charge value not stated as a single figure). Affected businesses generated approximately $37.3 million of 2004 sales.
2004-12-31restructuringcompleted1362003-07-012004-12-31United States and EuropeWorldwideUSD 13 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charge recorded in July 2003 associated with decision to streamline operations. Reducing worldwide workforce by 136 employees, primarily in the United States and Europe. As of December 31, 2004, $0.3 million of the charge remained unpaid.
2004-12-31restructuringannounced602005-01-26JapanCardiopulmonary products and pacemaker distributionsubsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced January 26, 2005. Sale of cardiopulmonary products business in Japan and exit from pacemaker distribution business. Transactions will result in transfer or elimination of approximately 60 full-time positions. Charge expected in first quarter of 2005 between $6 million and $9 million.
2004-12-31restructuringcompleted1362003-07WorldwideUSD 13 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Decision to streamline operations in July 2003; primarily US and Europe. Charge recorded in 2003, but $0.3 million remained unpaid as of Dec 31, 2004.
2004-12-31restructuringannounced602005-01-26JapanUSD 8 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Announced Jan 26, 2005: Exiting pacemaker distribution business and restructuring Japanese operations. Transfer or elimination of approx 60 full-time positions. Charge estimated between $6 million and $9 million in Q1 2005.
2004-03-31acquisition_additioncompleted2004-02-062004-01-27United StatesHeart Valve TherapyUSD 81 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Percutaneous Valve Technologies, Inc. for $125.0M cash plus up to $30.0M milestones; $81.0M charged to in-process R&D. Headcount added not disclosed.
2004-03-31restructuringcompleted2004-06-30not specifiedVascularUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of Lifepath AAA endovascular graft sales effort; charge primarily for inventory and contractual clinical obligations. Employee count not disclosed.
2004-03-31restructuringin_progress2004-09-30JapanOther Distributed ProductsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to discontinue certain lower-margin cardiology products in Japan later in 2004; charge primarily for non-productive assets. Employee count not disclosed.
2004-03-31restructuringcompleted2004-03-31VascularUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Discontinuation of Lifepath AAA endovascular graft program sales effort; charge related to inventory and contractual clinical obligations.
2004-03-31restructuringcompleted2004-03-31JapanCardiologyUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Discontinuation of certain lower margin cardiology products; charge related to other non-productive assets.
2003-12-31restructuringcompleted1362003-07-012003-12-31Primarily United States and EuropeWorldwide operationsUSD 13 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		July 2003 charge to streamline operations; $4.1 million of the charge remained unpaid at 2003-12-31. Announcement date is month-level (July 2003) only.
2003-12-31divestiture_reductioncompleted2003-07-042003-07-04GermanyPerfusion servicesUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		German perfusion services subsidiary sold to WKK GmbH for a nominal amount; impairment charge recorded to reduce carrying value to fair value. Headcount of the divested subsidiary not disclosed; subsidiary had approximately $3.5 million of sales in the six months ended 2003-06-30.
2003-12-31acquisition_additioncompleted2003-12-052003-12-05United KingdomCritical care monitoring technologiesUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired the stock of Whitland Research Limited for $3.2 million cash (up to $5.6 million with milestones through 2006); $1.8 million charged to in-process R&D and $1.4 million to patents. Headcount added not disclosed.
2003-12-31acquisition_additionannounced2004-01-272004-01-27United States (Fort Lee, New Jersey) and IsraelHeart valve therapy — percutaneous aortic valve replacementsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Percutaneous Valve Technologies, Inc. for $125.0 million cash plus up to $30.0 million in milestones through 2007; expected in-process R&D charge of $60.0–$90.0 million in Q1 2004. Headcount added not disclosed.
2003-12-31restructuringcompleted1362003-07-01United States and EuropeUSD 13 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Decision to streamline operations; primarily in the United States and Europe.
2003-12-31restructuringcompleted1362003-07WorldwideUSD 13 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Decision to streamline operations; primarily in the United States and Europe.
2003-09-30restructuringin_progress136Primarily United States and EuropeCompany-wideUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded during Q3 2003 to streamline operations; $9.6M after-tax; $9.3M of the charge remained unpaid at 2003-09-30. Specific announcement date not disclosed.
2003-09-30divestiture_reductioncompleted2003-07-042003-07-04GermanyPerfusion servicesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		German perfusion services subsidiary sold for a nominal amount; $3.3M pre-tax impairment charge recorded in Q2 2003 to reduce carrying value to fair value. Number of employees affected not disclosed.
2003-09-30restructuringin_progress1362003-09-30WorldwideUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge associated with decision to streamline operations; mostly in US and Europe. $9.3 million remained unpaid as of Sept 30, 2003.
2003-09-30otherannounced2003-11-042003-12-31Puerto RicoUSD 2 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Suspension of defined benefit pension plan effective Dec 31, 2003; employees will not earn additional defined benefits.
2003-06-30reduction_in_forceannounced2.5%2003-08-01WorldwideUSD 8 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced August 1, 2003, after quarter end; approximately 2.5% workforce reduction of about 5,000 employees worldwide. Affected-employee count not explicitly stated. Estimated after-tax charge of $8.0 to $10.0 million expected to be recorded in the quarter ended September 30, 2003; associated_charge_value records the low end of the disclosed range. Completion timing not specified.
2003-06-30divestiture_reductioncompleted2003-07-04GermanyPerfusion servicesUSD 3 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		German perfusion services subsidiary sold to WKK GmbH for a nominal amount, effective July 4, 2003 (subsequent to quarter end); subsidiary generated approximately $3.5 million of sales in the six months ended June 30, 2003. Headcount impact not disclosed. Associated charge is the $3.3 million pre-tax asset impairment recorded in Q2 2003, not a severance cost.
2003-06-30restructuringannounced1252.5%2003-08-012003-09-30WorldwideUSD 9 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced August 1, 2003. Expected charge of $8.0 to $10.0 million after-tax during Q3 2003. Represents approx 2.5% reduction of 5,000 employees.
2002-12-31acquisition_additioncompleted2002-10-012002-10-01JapanCardiovascular business (Japan)USD 3 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company acquired the cardiovascular business in Japan from Baxter for $19.0 million net, effective October 1, 2002; results fully consolidated from that date. The $3.3 million charge was for legal, administrative and regulatory expenses, not severance. No employee count disclosed.
2002-12-31restructuringcompleted2252000-08-312001-12-31Europe, United States, Puerto RicoManufacturingUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges established in 2000 for Jostra Sale; utilized in 2000 and 2001. Impacted approx 225 employees primarily in manufacturing.
2002-12-31restructuringcompleted2252000-08-312001-12-31Europe, United States, Puerto RicoManufacturingUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Reserves established in 2000 for personnel costs related to Jostra Sale. Fully utilized by end of 2001.
2002-12-31acquisition_additioncompleted2002-10-012002-10-01JapanCardiovascular business (all functions)USD 3 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company acquired the cardiovascular business in Japan from Baxter for $19.0 million net, effective October 1, 2002; Japan results consolidated from that date. The $3.3 million charge recorded in Q3 2002 covers legal, administrative and regulatory expenses, not severance. No employee count disclosed.
2002-12-31divestiture_reductioncompleted2002-12-312002-12-31International (various countries outside the United States)Distribution / salesItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Substantially all Baxter service agreements and distribution relationships outside the United States were terminated as of December 31, 2002, with the Japan distribution agreement ending upon the October 1, 2002 acquisition. No headcount impact quantified.
2002-09-30acquisition_additioncompleted2002-07-252002-10-01JapanCardiovascular business (Japan joint venture with Baxter International Inc.)USD 3 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company acquired the Japan cardiovascular business for approximately $22 million net, completing its spin-off from Baxter; a $3.3 million charge for legal, administrative and regulatory expenses was recorded in Q3 2002. No employee headcount added was disclosed.
2002-06-30acquisition_additionannounced2002-07-252002-10-01JapanCardiovascular business (Japan joint venture)USD 3 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement with Baxter to terminate the Japan joint venture and acquire the Japanese business; no employee count disclosed. Estimated transaction price ~$25 million net; ~$3 million one-time transaction expenses and ~$4 million capital investment expected through 2002-12-31. Subject to regulatory approvals.
2001-12-31divestiture_reductioncompleted2001-06-302001-06-30United States and Puerto RicoPerfusion services (contract perfusionists, monitoring systems, capital equipment)USD 68 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Edwards Lifesciences Cardiovascular Resources, Inc. stock to a Fresenius Medical Care AG affiliate for $45 million cash; $68 million pre-tax loss on sale. Headcount of the divested services business not disclosed.
2001-12-31restructuringcompleted2000-06-302001-12-31Europe, United States and Puerto RicoPerfusion products manufacturing (Jostra AG sale program)USD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2001 activity only: $8 million of the original $10 million personnel-cost reserve was utilized during 2001, exhausting the balance at year-end. The program's 225 impacted employees were disclosed in the 2000 initiative; no separate FY2001 affected-employee count is given.
2001-12-31othercompletedNot specifiedNon-strategic products and distributed productsUSD 15 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2001 discontinuation of sales efforts for certain non-strategic products; $15 million non-cash impairment (intangibles $9M, investment $5M, non-productive assets $1M). No headcount impact quantified.
2001-12-31restructuringcompleted2252000-08-312001-12-31Europe, United States, Puerto RicoManufacturingUSD 12 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Personnel costs consisted primarily of severance, medical plan continuation and outplacement services for approximately 225 employees impacted by the Jostra Sale. Reserves established in 2000 were fully utilized by December 31, 2001.
2001-12-31divestiture_reductioncompleted2001-06-302001-06-30United States, Puerto RicoPerfusion ServicesUSD 68 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of Edwards Lifesciences Cardiovascular Resources, Inc. (ELCR) to Fresenius Medical Care AG. ELCR provided and managed perfusionists, monitoring systems, capital equipment and disposable material. Specific headcount not disclosed.
2001-06-30divestiture_reductioncompleted2001-06-302001-06-30United States and Puerto RicoPerfusion products and services (Edwards Lifesciences Cardiovascular Resources, Inc.)USD 68 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of ELCR stock to Fresenius Medical Care AG for $45 million cash; $68.2 million pre-tax loss on sale. ELCR had roughly $30 million of net sales in Q2 2001; no employee count disclosed.
2001-06-30otherannounced12001-05-032001-12-31United StatesCorporate — Corporate Vice President, North Americaother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Individual executive transition: officer status and duties end 2001-07-27; continued employment at current salary plus consulting availability until voluntary retirement on 2001-12-31. Founders and Transition options expire 2001-12-31; no change-in-control severance triggered.
2000-12-31divestiture_reductioncompleted2252000-07-152000-08-31Europe, United States, Puerto RicoPerfusion products — manufacturingUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of majority of US and Western European perfusion product assets to Jostra AG; $10M personnel cost reserve (severance, medical plan continuation, outplacement) plus $2M exit activities reserve; $4M utilized through year-end, $8M remaining
2000-12-31restructuringcompleted2252000-07-152000-12-31Europe, United States, Puerto RicoManufacturingUSD 12 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Personnel costs reserve of $10 million and exit activities reserve of $2 million established in Q3 2000 related to sale of perfusion products to Jostra AG. Approximately 225 employees impacted, primarily in manufacturing capacity.
2000-12-31restructuringcompleted2252000-07-152000-12-31Europe, United States, Puerto RicoManufacturingUSD 10 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Personnel costs related to sale of perfusion products to Jostra AG. Includes severance, medical plan continuation, and outplacement services.
2000-09-30divestiture_reductioncompleted2252000-07-15Europe, United States, Puerto RicoPerfusion Products and Services (manufacturing)USD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Personnel costs charge covers severance, medical plan continuation and outplacement for employees impacted by the Jostra AG sale; $9.3M of the $9.7M reserve remained unspent at quarter-end.
2000-09-30plant_closurein_progress2000-07-15United States, EuropePerfusion Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exit activities charge covers information systems costs, contract terminations and shutdown expenses tied to the Jostra AG divestiture; $1.0M of the $2.0M reserve remained at quarter-end.
2000-09-30restructuringcompleted2252000-07-15Europe, United States, Puerto RicoPerfusion products (manufacturing)USD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of perfusion products assets to Jostra AG. Charge includes $9.7M for personnel costs (severance, medical plan continuation, outplacement) and $2.0M for exit activities. Employees primarily in manufacturing capacity.
2000-06-30divestiture_reductionannounced2000-07-152000-09-30United States and Western EuropePerfusion Products and ServicesUSD 10 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of majority of US and Western European perfusion assets to Jostra AG; $10M pre-tax personnel charge expected in Q3 2000 covering severance, medical plan continuation, and outplacement. No employee count disclosed.
2000-06-30divestiture_reductioncompleted2000-05-242000-06-30United StatesCardiac Surgery — Mechanical Cardiac Assistother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Transfer of mechanical cardiac assist product line rights, IP, and US assets to World Heart Corporation effective June 30, 2000. Employees of the transferred business were offered continued employment by Newco (Valentine Acquisition Corp.). No employee count disclosed.
2000-06-30restructuringin_progress2000-06-30GlobalMultiple discontinued product linesUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Non-cash charge of $45M for impairment of goodwill ($37M), other intangibles ($5M), and non-productive assets ($3M) related to discontinued products. No employee count disclosed.
2000-06-30restructuringannounced2000-07-152000-09-30United States and Western EuropePerfusion ProductsUSD 10 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company entered into agreement to sell majority of US and Western European perfusion assets. Anticipates incurring additional $10 million pre-tax charge in Q3 2000 related to personnel costs (severance, medical plan continuation, outplacement) for employees expected to be terminated. No payments made as of July 31, 2000.